EGFR Signaling and Drug Discovery
The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
Dysregulation of human epidermal growth factor receptor (ErbB/HER) pathways by over-expression or constitutive activation can promote tumor processes including angiogenesis and metastasis and is associated with poor prognosis in many human malignancies. In addition to cancer, ErbB signaling has also been implicated in cardiovascular and neurodegenerative diseases. Conversely, inhibition of ErbB pathways with targeted agents, such as monoclonal antibodies (MoAbs) or tyrosine kinase inhibitors (TKIs), blocks cell cycle progression, inhibits the production of pro-angiogenic factors and induces apoptosis in numerous in vitro and xenograft models. Accordingly, the ErbB receptor family with their most prominent members EGFR and HER-2 represents validated targets for anti-cancer therapy, and anti-ErbB MoAbs (cetuximab, panitumumab, and trastuzumab) and TKIs (gefitinib, erlotinib, and lapatinib) have now been approved for the treatment of advanced colorectal cancer, squamous cell carcinoma of the head and neck, advanced non-small-cell lung cancer, as well as pancreatic and breast cancer. Although results have been encouraging, more work remains to be done.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“In addition to EGFR (ERBB1), HER-2 (ERBB2) was first recognized over 20 years ago when it was found to be overexpressed in 30p of invasive breast cancers and shown to correlate inversely with time to tumor recurrence and overall survival (OS) [”
BackgroundLynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“The recently reported phase III BR.21 clinical trial demonstrated that erlotinib, unlike gefitinib, produced a survival advantage relative to placebo in patients with incurable NSCLC who had not responded to one or two prior chemotherapy regimens. In this study, over 700 patients were randomly assigned in a 2:1 ratio…”
BackgroundInfluentialRadiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 1×
“Regulatory approval of cetuximab was based on a pivotal European trial (BOND), where patients were randomly assigned to receive cetuximab alone or cetuximab in combination with CPT-11. The study of >300 patients showed a response rate of 22.9 and 10.8p (p = 0.007) for the combination and mono-chemotherapy groups, resp…”
InfluentialDarnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Cited by
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Role of epidermal growth factor receptor in breast cancer
Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2289-9 · Cited by 806
Insight into nanoparticle cellular uptake and intracellular targeting
Yameen, B., Choi, W. I., Vilos, C., Swami, A., Shi, J., & Farokhzad, O. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.038 · Cited by 787
The pros and cons of phytoestrogens
Patisaul, H. B., & Jefferson, W. (2010) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.03.003 · Cited by 746
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
PLGA-Based Nanoparticles as Cancer Drug Delivery Systems
Tabatabaei Mirakabad, F. S., Nejati-Koshki, K., Akbarzadeh, A., Yamchi, M. R., Milani, M., Zarghami, N., Zeighamian, V., Rahimzadeh, A., Alimohammadi, S., Hanifehpour, Y., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.2.517 · Cited by 542
Powell, A. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., Telli, M. L., Advani, R. H., Carlson, R. W., Mollick, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033788 · Cited by 531
Nanoparticles and targeted drug delivery in cancer therapy
Bahrami, B., Hojjat-Farsangi, M., Mohammadi, H., Anvari, E., Ghalamfarsa, G., Yousefi, M., & Jadidi-Niaragh, F. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.07.015 · Cited by 510
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Bergamo, A., & Sava, G. (2011) · Dalton Transactions · doi:10.1039/c0dt01816c · Cited by 440
Polymeric nanoparticles for targeted treatment in oncology: current insights
Joshi, M. D., Patravale, V., & Prabhu, R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s56932 · Cited by 438
Wang, Z. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 430
Multifunctional dendritic polymers in nanomedicine: opportunities and challenges
Khandare, J., Calderón, M., Dagia, N. M., & Haag, R. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15242d · Cited by 418
Xu, J., Chen, Y., & Olopade, O. I. (2010) · Genes & Cancer · doi:10.1177/1947601910378691 · Cited by 382
Han, W., Pan, H., Chen, Y., Sun, J., Wang, Y., Li, J., Ge, W., Feng, L., Lin, X., Wang, X., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018691 · Cited by 256
Proteomic data from human cell cultures refine mechanisms of chaperone-mediated protein homeostasis
Finka, A., & Goloubinoff, P. (2013) · Cell Stress and Chaperones · doi:10.1007/s12192-013-0413-3 · Cited by 218
Chen, X.-S., Wang, K.-S., Guo, W., Li, L.-Y., Yu, P., Sun, X.-Y., Wang, H.-Y., Guan, Y.-D., Tao, Y.-G., Ding, B.-N., et al. (2020) · Theranostics · doi:10.7150/thno.39814 · Cited by 58
In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells
Luca, T., Barresi, V., Privitera, G., Musso, N., Caruso, M., Condorelli, D. F., & Castorina, S. (2014) · Cell Proliferation · doi:10.1111/cpr.12125 · Cited by 27
Metadata
- Authors
- Lurje, G., & Lenz, H.-J.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 77
- Issue
- 6
- Pages
- 400-410
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2009644972
- Cited by
- 442
- References
- 108
- FWCI
- 22.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.